N-803 + Standard Care for Non-Small Cell Lung Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you must stop taking your current medications. However, you cannot take medications that have an adverse reaction with the study drugs. It's best to discuss your current medications with the trial team.
What data supports the effectiveness of the drug combination N-803 + Standard Care for Non-Small Cell Lung Cancer?
What safety data exists for N-803 + Standard Care for Non-Small Cell Lung Cancer?
Research shows that treatments involving nab-paclitaxel (a form of chemotherapy) combined with carboplatin have been studied for safety in non-small cell lung cancer. These studies generally focus on the safety and side effects of these drugs, which are important to consider when evaluating treatment options.12346
What makes the drug combination of N-803, Carboplatin, Nab-paclitaxel, Pembrolizumab, and Pemetrexed unique for treating non-small cell lung cancer?
This drug combination is unique because it includes N-803, an IL-15 superagonist complex, which is designed to boost the immune system's response against cancer cells, alongside a mix of chemotherapy agents like Carboplatin, Nab-paclitaxel, and Pemetrexed, and the immunotherapy drug Pembrolizumab, which helps the immune system recognize and attack cancer cells. This multi-faceted approach aims to enhance treatment effectiveness by combining immune system activation with traditional chemotherapy.12347
What is the purpose of this trial?
This trial tests N-803 with standard treatments for patients with severe lung cancer. N-803 aims to boost the immune system to fight cancer cells more effectively.
Research Team
Paula Bradshaw
Principal Investigator
Vice President, Clinical Business Operations
Eligibility Criteria
This trial is for adults with stage 3 or 4 non-small cell lung cancer (NSCLC) who haven't had systemic chemotherapy for advanced/metastatic NSCLC. They must have tumors without certain genetic mutations, measurable tumor lesions, and an ECOG performance status of 0 or 1. Participants need to provide consent, tissue samples, agree to contraception use if applicable, and not be candidates for surgery or chemoradiation.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive N-803 in combination with chemoimmunotherapy containing approved CPIs as first-line treatment for up to 2 years
Follow-up
Participants are monitored for disease progression, post-therapies, and survival
Treatment Details
Interventions
- Carboplatin
- N-803
- Nab-paclitaxel
- Pembrolizumab
- Pemetrexed
Carboplatin is already approved in United States, European Union, Canada for the following indications:
- Ovarian cancer
- Testicular cancer
- Lung cancer
- Head and neck cancer
- Brain cancer
- Ovarian cancer
- Small cell lung cancer
- Ovarian cancer
- Small cell lung cancer
- Testicular cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
ImmunityBio, Inc.
Lead Sponsor
Richard Adcock
ImmunityBio, Inc.
Chief Executive Officer since 2024
Information not available
Dr. Patrick Soon-Shiong
ImmunityBio, Inc.
Chief Medical Officer since 2021
MD